Sun Pharma gets US FDA nod for anti-cancer drug Gleevec
The Imatinib Mesylate tablets are meant for the treatment of chronic myeloid leukaemia and Sun Pharma will launch them in the US on 1 February 201604-12-2015
04-12-2015
Sun Pharma announces US FDA approval for generic Gleevec
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated December 04, 2015 titled "Sun Pharma announces US FDA approval for generic Gleevec".04-12-2015
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jayant S Sanghvi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE03-12-2015
Brokers turn bullish on Sun Pharma
Morgan Stanley said it was overweight on the stock and there was 22% upside in the counter in the next 12 months. The brokerage house has set a price target of Rs 981.03-12-2015
Updates
Sun Pharmaceutical Industries Ltd has informed BSE that pursuant to Regulation 30(5) of the Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, Mr. Dilip Shanghvi, Managing Director, Mr. Sudhir V. Valia, Whole Time Director, Mr. Sailesh Desai Whole Time Director, Mr. Uday Baldota, CFO and Mr. Sunil Ajmera, Company Secretary have been authorised severally to determine materiality of an event...01-12-2015
Sun Pharma: Valuations factor in the downsides
Its presence in niche areas acts a strong entry barrier, investors are keeping an eye on triggers related to launches going ahead30-11-2015
Sun Pharma gains as Taro drops wind energy investment
In past one-month, the stock underperformed the market by declining 20% as compared to 6% drop in the Sensex.26-11-2015
Sun Pharma drops wind energy investment plan
Move has not gone down well with analysts, who termed the proposed investment a non-optimal use of cash25-11-2015
Updates on Subsidiary - Wind Energy Project Update
Sun Pharmaceutical Industries Ltd has informed BSE that some of the Company's subsidiaries were contemplating an investment in a wind energy project in the US. Subsequent to a further evaluation, these subsidiaries have decided not to proceed with this potential project.24-11-2015
Updates on NCD
Sun Pharmaceutical Industries Ltd has informed BSE that the Company has made payment of interest on and redemption amount pertaining to 5,000 Secured Rated Redeemable Non-Convertible Debentures (NCD) of the face value of Rs. 10,00,000 each aggregating to Rs. 500 Crores (listed on National Stock Exchange of India Ltd), on November 23, 2015 to the NCD holders of the Company whose names stand registered on the Register of beneficial owners maintained...23-11-2015